CN111132694B - 治疗阿尔茨海默病的组合物和方法 - Google Patents

治疗阿尔茨海默病的组合物和方法 Download PDF

Info

Publication number
CN111132694B
CN111132694B CN201880045403.4A CN201880045403A CN111132694B CN 111132694 B CN111132694 B CN 111132694B CN 201880045403 A CN201880045403 A CN 201880045403A CN 111132694 B CN111132694 B CN 111132694B
Authority
CN
China
Prior art keywords
stat1
ch25h
app
inhibitor
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880045403.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111132694A (zh
Inventor
傅新元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jianaisi Biomedical Co ltd
Original Assignee
Jianaisi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jianaisi Biomedical Co ltd filed Critical Jianaisi Biomedical Co ltd
Priority to CN202411664773.XA priority Critical patent/CN119488598A/zh
Publication of CN111132694A publication Critical patent/CN111132694A/zh
Application granted granted Critical
Publication of CN111132694B publication Critical patent/CN111132694B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99038—Cholesterol 25-hydroxylase (1.14.99.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880045403.4A 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法 Active CN111132694B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411664773.XA CN119488598A (zh) 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506782P 2017-05-16 2017-05-16
US62/506,782 2017-05-16
PCT/US2018/031901 WO2018213081A1 (en) 2017-05-16 2018-05-09 Compositions and methods for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411664773.XA Division CN119488598A (zh) 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法

Publications (2)

Publication Number Publication Date
CN111132694A CN111132694A (zh) 2020-05-08
CN111132694B true CN111132694B (zh) 2024-12-03

Family

ID=64274628

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880045403.4A Active CN111132694B (zh) 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法
CN202411664773.XA Pending CN119488598A (zh) 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411664773.XA Pending CN119488598A (zh) 2017-05-16 2018-05-09 治疗阿尔茨海默病的组合物和方法

Country Status (9)

Country Link
US (1) US11873321B2 (https=)
EP (1) EP3628008A4 (https=)
JP (2) JP7675502B2 (https=)
KR (1) KR20200010311A (https=)
CN (2) CN111132694B (https=)
AU (1) AU2018270906B2 (https=)
CA (1) CA3063217A1 (https=)
TW (1) TW201900216A (https=)
WO (1) WO2018213081A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법
CN111500694B (zh) * 2019-01-31 2023-02-24 中国科学院脑科学与智能技术卓越创新中心 Baz2b基因作为靶点在缓解衰老中的应用
JP2023521646A (ja) * 2020-03-31 2023-05-25 ウィルフレッド ジェフリーズ アルツハイマー病の治療方法
CA3259413A1 (en) * 2022-06-13 2023-12-21 The University Of Queensland USES OF JAK INHIBITORS IN THE MANAGEMENT OF DEPRESSION AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES ASSOCIATED WITH INFLAMMATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168800A1 (en) * 2014-05-09 2015-11-12 UNIVERSITé LAVAL Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US8771700B2 (en) * 2006-08-23 2014-07-08 Rutgers, The State University Of New Jersey Interferon antagonists, antibodies thereto and associated methods of use
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US9987224B2 (en) * 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
ES2731437T3 (es) * 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168800A1 (en) * 2014-05-09 2015-11-12 UNIVERSITé LAVAL Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Richard Lathe.Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols,vasculature.《BMC Geriatrics》.2014,第14卷(第36期),第17-18页. *
STAT1 Negatively Regulates Spatial Memory Formation and Mediates the Memory-Impairing Effect of Ab;Wei-Lun Hsu;《Neuropsychopharmacology》;第39卷(第3期);摘要、介绍、结果、讨论部分和图2 *
Wei-Lun Hsu.STAT1 Negatively Regulates Spatial Memory Formation and Mediates the Memory-Impairing Effect of Ab.《Neuropsychopharmacology》.2013,第39卷(第3期),摘要、介绍、结果、讨论部分和图2. *

Also Published As

Publication number Publication date
EP3628008A4 (en) 2021-04-28
KR20200010311A (ko) 2020-01-30
CN119488598A (zh) 2025-02-21
JP2022174207A (ja) 2022-11-22
JP7675502B2 (ja) 2025-05-13
AU2018270906B2 (en) 2024-02-29
TW201900216A (zh) 2019-01-01
CN111132694A (zh) 2020-05-08
AU2018270906A1 (en) 2019-12-19
EP3628008A1 (en) 2020-04-01
US11873321B2 (en) 2024-01-16
CA3063217A1 (en) 2018-11-22
US20200199239A1 (en) 2020-06-25
WO2018213081A1 (en) 2018-11-22
JP2020520931A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
Takalo et al. The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions
Dong et al. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease
El Gaamouch et al. VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice
Fiore et al. Sex‐specific transcriptome of spinal microglia in neuropathic pain due to peripheral nerve injury
Neumann et al. The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Way et al. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic
Borggrewe et al. VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases
Krasemann et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases
Goldmann et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain
Marsh et al. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function
JP2022174207A (ja) アルツハイマー病の治療用組成物および治療方法
Branchi et al. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration
Dineley et al. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice
Parkhurst et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor
Chen et al. CREB binding protein is required for both short-term and long-term memory formation
He et al. Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury
Halbach et al. Atxn2 knockout and CAG42-knock-in cerebellum shows similarly dysregulated expression in calcium homeostasis pathway
Tiwari et al. Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss
Brouwer et al. The FMR1 gene and fragile X‐associated tremor/ataxia syndrome
Lansdall An effective treatment for Alzheimer's disease must consider both amyloid and tau
Chen et al. Alzheimer’s amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway
Poeta et al. Histone demethylase KDM5C is a SAHA-sensitive central hub at the crossroads of transcriptional axes involved in multiple neurodevelopmental disorders
Faergeman et al. A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
Jones et al. Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice
US20210308077A1 (en) Combinations including beta-adrenoreceptor agonists for treatment of parkinson`s disease and movement disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022834

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant